Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard Prins sold 7,973 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total transaction of $161,851.90. Following the completion of the transaction, the director directly owned 29,625 shares in the company, valued at approximately $601,387.50. This trade represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $20.18 on Friday. The stock has a fifty day moving average of $19.81 and a 200-day moving average of $21.19. The firm has a market capitalization of $858.46 million, a P/E ratio of 11.94, a PEG ratio of 4.22 and a beta of 0.89. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $31.26. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.62 by $0.29. The business had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AMPH shares. Weiss Ratings restated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Finally, Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Six analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $22.00.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently bought and sold shares of the business. Algert Global LLC increased its position in Amphastar Pharmaceuticals by 110.7% during the second quarter. Algert Global LLC now owns 131,400 shares of the company’s stock worth $2,652,000 after buying an additional 69,040 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth about $39,000. Denali Advisors LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth about $7,587,000. Deutsche Bank AG bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth about $712,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth about $4,689,000. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.